UNSPSC 51144123: Levamfetamine

This classification denotes a cns stimulant with the molecular formula C9H13N.C4H6O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) STC9O9MD79, chemically known as butanedioic acid, compd. with (-)-alpha-methylbenzeneethanamine (1:1) but more generally known as levamfetamine succinate, which bears US NIH Compound Identifier 68638. Most nations, for tariff and trade purposes, schedule levamfetamine under HS 29214600 and SITC kg. As of Q4 2014, LEVAMFETAMINE remains US FDA's Preferred Term for this commodity.

SMILES: CC(CC1=CC=CC=C1)N.C(CC(=O)O)C(=O)O.

UNSPSC 51144123 Levamfetamine is a Commodity code that captures individual pharmaceutical products procured by state and local health agencies, though recent activity under this specific code does not reflect levamfetamine itself. Instead, the solicitations tagged to this code reflect state and local demand for naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesalers and direct-to-manufacturer channels. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida has solicited naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission has issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has posted a broad RFP for generic pharmaceuticals and OTC products available to participating state and local agencies across multiple jurisdictions.

Recent activity concentrates in Florida, Texas, and Minnesota, with MMCAP's cooperative purchasing vehicle extending eligibility to Oregon and other member jurisdictions. Seminole County's IFB (Solicitation IFB60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring vendors to include shipping costs and comply with E-Verify and drug-free workplace certification. MMCAP's RFP (Solicitation S1070000015802, due March 26, 2026) establishes multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. The Texas HHS Commission's RFI (HHS0017013, due April 3, 2026) explores vendor capacity for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements, signaling state interest in alternative supply-chain models for pharmaceutical procurement.